IL-1β exerted substantial anti-fibrogenic effects by reducing proliferation, matrix activity, cell motility, and α-smooth muscle actin expression in ventricular fibroblasts.
Does IL-1β suppress TGF-β-mediated myofibroblast differentiation in ventricular fibroblasts?
IL-1β may exert beneficial effects in cardiac fibrosis by actively suppressing the differentiation of cardiac fibroblasts into fibrogenic myofibroblasts.
Cardiac fibrosis is a maladaptive response of the injured myocardium and is mediated through a complex interplay between molecular triggers and cellular responses. Interleukin (IL)-1β is a key inflammatory inducer in cardiac disease and promotes cell invasion and cardiomyocyte injury, but little is known of its impact on fibrosis. A major cornerstone of fibrosis is the differentiation of cardiac fibroblasts (CFs) into myofibroblasts (myoFbs), which is highly promoted by Transforming Growth Factor (TGF)-β. Therefore, we asked how IL-1β functionally modulated CF-to-myoFb differentiation. Using a differentiation model of ventricular fibroblasts, we found that IL-1β instigated substantial anti-fibrogenic effects. In specific, IL-1β reduced proliferation, matrix activity, cell motility and α-smooth muscle actin expression, which are all hallmarks of myoFb differentiation. These findings suggest that IL-1β, besides from its acknowledged adverse role in the inflammatory response, can also exert beneficial effects in cardiac fibrosis by actively suppressing differentiation of CFs into fibrogenic myoFbs.
Brønnum et al. (Sat,) conducted a other in Cardiac fibrosis. IL-1β was evaluated on Cardiac fibroblast to myofibroblast differentiation. IL-1β exerted substantial anti-fibrogenic effects by reducing proliferation, matrix activity, cell motility, and α-smooth muscle actin expression in ventricular fibroblasts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: